cGAS-STING Pathway Inhibition for Chronic Neuroinflammation
📖 Wiki Page
idea1576 wordssynced 2026-04-02
cGAS-STING Pathway Inhibition for Chronic Neuroinflammation
Overview
This therapeutic strategy targets the cGAS-STING pathway — the innate immune DNA-sensing axis that converts mitochondrial and nuclear DNA damage into chronic type I interferon-driven neuroinflammation. In neurodegenerative diseases, damaged mitochondria leak DNA into the cytoplasm, activating cGAS (cyclic GMP-AMP synthase) → STING (Stimulator of Interferon Genes) → TBK1 → IRF3 → interferon-stimulated genes. This pathway is now recognized as a major driver of microglial activation, astrocyte reactivity, and neuronal death across Alzheimer's disease, Parkinson's disease, ALS, and FTD. Critically, TBK1 loss-of-function mutations cause familial ALS/FTD, directly linking this pathway to neurodegeneration genetics.[@decout2021][@paul2021]
Target
Primary Target: STING (TMEM173) palmitoylation site or trafficking domain; or cGAS catalytic domain
Expression: cGAS and STING are expressed in microglia, astrocytes, and at lower levels in neurons; upregulated in disease states
Localization: cGAS is cytoplasmic (senses dsDNA); STING resides at the ER membrane and traffics to Golgi upon activation
Mechanistic Rationale
The cGAS-STING pathway is the cell's primary sensor of cytoplasmic double-stranded DNA — a danger signal indicating viral infection, DNA damage, or mitochondrial stress. In neurodegeneration, multiple sources feed this pathway:[@decout2021]
...
cGAS-STING Pathway Inhibition for Chronic Neuroinflammation
Overview
This therapeutic strategy targets the cGAS-STING pathway — the innate immune DNA-sensing axis that converts mitochondrial and nuclear DNA damage into chronic type I interferon-driven neuroinflammation. In neurodegenerative diseases, damaged mitochondria leak DNA into the cytoplasm, activating cGAS (cyclic GMP-AMP synthase) → STING (Stimulator of Interferon Genes) → TBK1 → IRF3 → interferon-stimulated genes. This pathway is now recognized as a major driver of microglial activation, astrocyte reactivity, and neuronal death across Alzheimer's disease, Parkinson's disease, ALS, and FTD. Critically, TBK1 loss-of-function mutations cause familial ALS/FTD, directly linking this pathway to neurodegeneration genetics.[@decout2021][@paul2021]
Target
Primary Target: STING (TMEM173) palmitoylation site or trafficking domain; or cGAS catalytic domain
Expression: cGAS and STING are expressed in microglia, astrocytes, and at lower levels in neurons; upregulated in disease states
Localization: cGAS is cytoplasmic (senses dsDNA); STING resides at the ER membrane and traffics to Golgi upon activation
Mechanistic Rationale
The cGAS-STING pathway is the cell's primary sensor of cytoplasmic double-stranded DNA — a danger signal indicating viral infection, DNA damage, or mitochondrial stress. In neurodegeneration, multiple sources feed this pathway:[@decout2021]
Mitochondrial DNA leakage: Damaged mitochondria (common in all neurodegenerative diseases) release mtDNA through mPTP and BAX/BAK pores[@west2015]
Nuclear DNA damage: Age-related and disease-associated DNA damage produces cytoplasmic DNA fragments via nuclear envelope rupture
Tau-induced nuclear envelope disruption: Tau aggregates physically deform the nuclear envelope, releasing chromatin into the cytoplasm[@frost2016]
TDP-43 and C9orf72 pathology: TDP-43 mislocalization and C9orf72 repeat expansions impair nuclear pore function, increasing cytoplasmic DNA[@mccauley2020]
Once activated, cGAS produces cyclic GMP-AMP (cGAMP), which activates STING → TBK1 → IRF3, driving a sustained type I interferon response that causes:
Microglial polarization to neurotoxic DAM (disease-associated microglia) state
Astrocyte conversion to A1 reactive phenotype
Neuronal apoptosis via interferon-stimulated gene products
Complement activation and synapse elimination
Cross-links to relevant mechanisms:
cGAS-STING Pathway in Neurodegeneration
cGAS-STING Pathway
Neuroinflammation
Mitochondrial Dysfunction
Microglia and Neuroinflammation
Neuroinflammation Pathway
Rubric Score
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7/10 | cGAS-STING is well-known in innate immunity/oncology but CNS-selective inhibitors for neurodegeneration are unexplored clinically | | Mechanistic Rationale | 9/10 | Pathway validated in AD, PD, ALS, FTD; TBK1 mutations cause ALS/FTD; multiple mechanistic convergence points | | Addresses Root Cause | 7/10 | Addresses chronic neuroinflammation (a major disease amplifier) but not the upstream protein aggregation that generates cytoplasmic DNA | | Delivery Feasibility | 7/10 | H-151 and RU.521 are BBB-penetrant small molecules; oral dosing demonstrated in preclinical models | | Safety Plausibility | 6/10 | cGAS-STING is critical for antiviral defense; chronic inhibition may increase infection susceptibility; intermittent dosing or brain-selective compounds needed | | Combinability | 9/10 | Highly orthogonal to anti-aggregation therapies (addresses a different axis entirely); combines with anti-tau, anti-amyloid, and neuroprotective approaches | | Biomarker Availability | 8/10 | CSF type I interferons (IFN-α, IFN-β), CXCL10, and interferon-stimulated gene signatures in blood are validated PD markers | | De-risking Path | 8/10 | STING-knockout mice show neuroprotection in multiple disease models; H-151 tool compound well-characterized; iPSC microglia models available | | Multi-disease Potential | 9/10 | Validated in AD (tau+mtDNA), PD (α-syn+mtDNA), ALS (TDP-43+TBK1), FTD (tau+TBK1), aging (inflammaging) — exceptionally broad | | Patient Impact | 7/10 | Reducing chronic neuroinflammation could slow progression significantly; most impactful when combined with aggregate-clearing therapies | | Total | 77/100 | |
De-risking Path
Phase 1 — CNS-selective compounds: Optimize H-151 or develop novel STING inhibitors with enhanced BBB penetration and reduced peripheral immunosuppression (e.g., brain-accumulating prodrugs)
Phase 2 — Cellular validation: Demonstrate reduced IFN-β, CXCL10, and ISG expression in iPSC-derived microglia and astrocytes co-cultured with tau-aggregating or TDP-43-mislocalized neurons
Phase 3 — Model efficacy: Test in PS19 tau mice (neuroinflammation + tau), MPTP PD mice (mtDNA leakage), and TDP-43 ALS models; measure ISG reduction, microglial phenotype shift, and neuronal survival
Phase 4 — Safety: Assess infection susceptibility during chronic dosing; test intermittent dosing schedules (e.g., 5 days on / 2 days off) that maintain neuroprotection while preserving antiviral capacity
Phase 5 — Clinical: ALS-TBK1 mutation carriers as genetically enriched first-in-human population; CSF CXCL10 as primary PD endpoint
Disease Coverage
| Disease | Relevance | Rationale | |---------|-----------|-----------| | ALS/FTD | High | TBK1 is a STING effector; TBK1 LOF mutations cause ALS/FTD; TDP-43 mislocalization activates cGAS[@mccauley2020] | | Alzheimer's Disease | High | Tau disrupts nuclear envelope → cytoplasmic DNA; mtDNA leakage from damaged mitochondria activates cGAS[@frost2016] | | Parkinson's Disease | High | PINK1/Parkin mitophagy failure causes mtDNA accumulation; STING KO rescues PINK1-/- inflammation[@sliter2018] | | Frontotemporal Dementia | High | Tau and TDP-43 pathology both converge on cytoplasmic DNA sensing | | PSP/CBD | Medium | 4R tauopathy with nuclear envelope disruption; cortisol-tau pathway amplifies inflammation | | Aging/Inflammaging | Medium | Age-related mtDNA accumulation and DNA damage drive baseline cGAS-STING activation |
Combination Therapy Potential
With anti-tau therapies (antisense oligonucleotides, immunotherapy): Reduce tau aggregates (the upstream trigger) while simultaneously blocking the inflammatory amplification loop
With mitophagy enhancers: Urolithin A clears damaged mitochondria before they leak mtDNA, while STING inhibition blocks signaling from residual mtDNA
With NAD+ precursors: NAD+ supports DNA repair via PARPs and SIRT1, reducing the cytoplasmic DNA burden; STING inhibition handles the inflammatory response to remaining DNA
Related NeuroWiki Pages
cGAS-STING in Neurodegeneration | cGAS-STING Pathway
[Decout A, Katz JD, Venkatraman S, Bhatt P, The cGAS-STING pathway as a therapeutic target in inflammatory diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34002067/)
[Paul BD, Snyder SH, Bhatt P, Signaling by cGAS-STING in neurodegeneration, neuroinflammation, and aging (2021)](https://pubmed.ncbi.nlm.nih.gov/33277638/)
[West AP, Khoury-Hanold W, Staron M, et al, Mitochondrial DNA stress primes the antiviral innate immune response (2015)](https://pubmed.ncbi.nlm.nih.gov/25592248/)
[McCauley ME, O'Rourke JG, Bhatt P, et al, C9orf72 in myeloid cells suppresses STING-induced inflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32555455/)
[Sliter DA, Martinez J, Hao L, et al, Parkin and PINK1 mitigate STING-induced inflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29795029/)
[Yu CH, Davidson S, Harapas CR, et al, TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/33208928/)
[Haag SM, Gulen MF, Reymond L, et al, Targeting STING with covalent small-molecule inhibitors (2018)](https://pubmed.ncbi.nlm.nih.gov/29618801/)
[Lama L, Adeseko W, Mustelin T, et al, TBK1 kinase activity regulates innate immune responses to viral infection (2021)](https://pubmed.ncbi.nlm.nih.gov/34103369/)
[Ablasser A, Chen ZJ, cGAS in action: expanding roles in immunity and inflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31399004/)
[Gulen MF, Samson N, Bode C, et al, cGAS-STING drives ageing-related inflammation and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37532932/)